Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial

To examine whether androgen receptor (AR) CAG repeat length was associated with the risk of incident benign prostatic hyperplasia (BPH).

[1]  I. Thompson,et al.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[2]  K. Channer,et al.  Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. , 2008, European journal of endocrinology.

[3]  E. Savolainen,et al.  The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia. , 2008, DNA and cell biology.

[4]  I. Thompson,et al.  Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2007, The Journal of urology.

[5]  J. Kaufman,et al.  Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? , 2007, European journal of endocrinology.

[6]  J. Kaufman,et al.  Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  E. Metter,et al.  Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men. , 2005, Journal of applied physiology.

[8]  E. Bergstralh,et al.  Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. , 2004, American journal of epidemiology.

[9]  C. Weinberg,et al.  A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH , 2004, The Pharmacogenomics Journal.

[10]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[11]  J. Schleutker,et al.  Androgen receptor CAG polymorphism and prostate cancer risk , 2002, Human Genetics.

[12]  M. Marberger,et al.  Association of polymorphisms within androgen receptor, 5α‐reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men , 2002, The Prostate.

[13]  E. Giovannucci,et al.  Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. , 2002, Urology.

[14]  A. von Eckardstein,et al.  The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men , 2002, Diabetologia.

[15]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[16]  R. Kirby,et al.  The natural history of benign prostatic hyperplasia: what have we learned in the last decade? , 2000, Urology.

[17]  P. Kantoff,et al.  CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians , 1999 .

[18]  P. Kantoff,et al.  CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. , 1999, The Prostate.

[19]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. , 1999, Urology.

[20]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[22]  N. Breslow,et al.  The analysis of case-control studies , 1980 .

[23]  C. R. Moore.  Physiology of the Testes and Therapeutic Application of Male Hormone. , 1940, Bulletin of the New York Academy of Medicine.